updated 1/31/2011 7:16:27 AM ET 2011-01-31T12:16:27

DALLAS, Jan. 31, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/ARNA

Arena Pharmaceuticals (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs) in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's advanced drug candidate is lorcaserin, for weight management, which has completed a pivotal Phase III clinical trial program. It submitted a new drug application (NDA) for lorcaserin to the U.S. Food and Drug Administration (FDA) for regulatory approval in December 2009. The FDA then issued a Complete Response Letter (CRL) in October 2010, outlining non-clinical and clinical reasons for its decision to not approve the drug, and provided recommendations relating to addressing the issues it raised in the CRL. 

For only $19 a month, you can sign up for our real-time stock alert service.  Click here to join now:   http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"Shares of ARNA slumped last week on news that the FDA is requesting more safety studies to approve its experimental weight-loss drug, lorcaserin -- suggesting a possible delay in the drug's launch. The FDA asked the Company to provide additional studies, including a separate 12-month trial in female rats to determine whether transient prolactin elevation mediated by short-term exposure to lorcaserin can result in mammary tumors in rats.

"'Our ongoing discussions with the FDA reflect our commitment to addressing the issues raised in the CRL to the agency's satisfaction,' ARNA president and CEO Jack Lief said in statement. 'We now have a greater understanding of the FDA's position as we move forward with our plans to resubmit the lorcaserin NDA.'"

To read the entire report visit: www.microstockprofit.com/lp/ARNA

See what investors are saying about ARNA at http://www.stockhideout.com

Get breaking news on ARNA at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.19%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.40%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.12%
17.11%
Source: Bankrate.com